The Imbalance Between Type 17 T-Cells And Regulatory Immune Cell Subsets In Psoriasis Vulgaris

The document discussed the imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris, highlighting the role of IL-17 producing T-cells in the disease. It noted that biologic treatments targeting IL-17 or IL-23 were effective but costly and required continuous administration to prevent recurrence, with 84% of patients relapsing within 52 weeks after stopping treatment. The study, involving 13 psoriasis patients and 5 healthy volunteers, identified distinct T17 cell subsets and dysfunctional regulatory T-cells contributing to disease progression. It emphasized the need to understand immune tolerance dysfunction for lasting remission and explored new technologies like single-cell RNA sequencing to study immune cell subsets. The findings suggested that targeting a broader spectrum of immune cells could improve psoriasis treatment, with ongoing clinical trials testing monoclonal antibody treatments for long-term remission.